Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...

A GRAN who shed more than five stone on Mounjaro is now fundraising to have surgery abroad – as she compares her saggy skin ...

I never imagined that coming off a medication could feel like stepping off a cliff. But here I am, bracing for the freefall.

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

Shivaji Dasgupta, an autonomous Brand Consultant, writes that India’s obsession with shortcuts risks turning a breakthrough ...

Many people using GLP-1 weight-loss drugs like Ozempic, Wegovy or Mounjaro regain the weight after stopping-experts explain ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

The U.S. is slashing funding for scientific research, after decades of deep investment. Here’s some of what those taxpayer dollars created.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...